echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > Genfit's PPAR alpha/double agonist elafibranor is eligible for orphan medicine by FDA and EMA

    Genfit's PPAR alpha/double agonist elafibranor is eligible for orphan medicine by FDA and EMA

    • Last Update: 2020-06-08
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    PBC is a rare liver disease, mainly due to the bile duct (functioning to transport bile out of the liver) by autoimmune damage, resulting in bile siltation, inhibits the liver's ability to remove toxins from the body, and leads to liver tissue scarring, i.ecirrhosisThe(http:// of Genfitannouncedthat the u.SFood andMedicines(http://Administration (
    FDA(http://) and the EuropeanDrug(http://Authority (HTTP://WWW.CHEMDRUG.COM/) have granted its lead drug, PPAR alpha/double agitator, the treatment of primary bile bile ductitis (PBC) orphan drug
    In April 2019, the FDA also granted elafibranor breakthrough drug eligibility (BTD) for the treatment of adult Patients with under-responsive Psychedelic acid (UDCA) in bears   About elafibranor
    elafibranor is a first-of-the-first(first-in-class) peroxidase-activating receptor alpha and pyridox (PPAR alpha/synostic) double agonist, and positive safety and efficacy results have been obtained in pBC adult patients who treated UDCA in phase II   Currently, elafibranor is also evaluating the potential for treatment of non-alcoholic fatty hepatitis (NASH) in Phase III clinical studies   The study the BTD grant, based on data from a randomized, double-blind, placebo-controlled Phase II clinical study, in adult patients with inadequate Response to UDCA   The results showed that elafibranor significantly reduced the level of alkaline phosphatase (ALP), showed significant therapeutic effect in the primary endpoint compared to placebo, and also reached the compound endpoint for drug registration   In addition to a significant reduction in ALP, other PBC markers in the two groups, including gamma-glutamine transferase (GGT), lipid markers (total cholesterol, LDL and triglycerides), and anti-inflammatory markers (IgM, CRP, binding belitosin, and fibrinogen), also showed improvements   In terms of safety
    studies, 2 doses of elafibranor were well tolerated Genfit plans to launch Phase III clinical studies in 2019 to further evaluate the efficacy and safety of elafibranor's treatment of PBC
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.